bullish

Innovent Biologics Inc

Innovent Biologics Inc (1801.HK) - Innovent Is Not Optional but Necessary in Portfolio

Innovent would transform from a biotech to biopharma. It is a better comprehensive choice of certainty, elasticity and safety than Hengrui. Its market value could reach RMB80 billion to RMB120 billion

Equity Bottom-Up
288 Views, 21 Jul 2022 08:59
SUMMARY(Sign Up to Access)
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
  • Unlimited Research Summaries
  • Personalised Alerts
  • Custom Watchlists
  • Company Data & News
  • Events & Webinars
or
Trusted by:
Bloomberg
Societe Generale
SGX
Sequoia
Interactive Broker
Refinitiv
Already have an account? Sign In Now
Full Insight
(Paid Plans Only)
Discussions
(Paid Plans Only)
WHAT’S TRENDING
Insights
  • Trending
  • Latest
Logo
Top Quartile
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
ChinaHealth CareEquity Bottom-UpThematic (Sector/Industry)
Price Chart(Sign Up to Access)
analytics-chart
  • China Resources Medical - Hard to Earn High Profits Due to Poor Business Model and Policy Risk
    25 Jul 2022
  • China Healthcare Weekly (July22)-Jiangsu Province VBP, CStone's Potential Sale, Irrational Mr Market
    24 Jul 2022
  • Pre-IPO Best Wellness Innovation Group - Here Are the Concerns
    22 Jul 2022
  • Innovent Biologics Inc (1801.HK) - Innovent Is Not Optional but Necessary in Portfolio
    21 Jul 2022
  • Shanghai Junshi Bioscience Placement- Junshi Is Having a Hard Time, with Lower than Expected Returns
    14 Jun 2022
  • BeiGene Ltd (6160.HK/BGNE.US/688235.CH) - Valuation Remodeling if the TIGIT Project Fails
    17 May 2022
  • Re-Examine the Outlook and Investment Strategy for China Biotech and CXO
    11 May 2022
  • Jiangsu Hengrui Medicine (600276.CH) 2021/2022Q1 Results - Can You Afford to Wait?
    04 May 2022
  • Innovent Biologics Inc (1801.HK) - Capable of Surviving “this Winter”
    04 Apr 2022
x